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The transcutaneou s absorption of a 1% lindane cream 
(Kwell) was determined after application according to 
the official label. By 3 days after application the p lasma 
lindane level increased from nondetectable to 10.3 ± 2.2 
ngj ml. S ufficient lindane was absorbed to increase the 
plasma clearance of antipyrine from 0.027 ± 0.009 to 
0 037 ± 0.011 1/kg/hr (p < 0.05). These findings indicate 
significant transcutaneous absorption of lindane occurs 
following a single application and are compatible with 
the neurological toxicity reported following the topical 
application of lindane cream. 
Gamma benzene hexachloride (lindane) in the form of a 1% 
cream shampoo or lotion is cunently recommended for the 
treat~ent of infestations of scabies and pediculi [1). Systemic 
absorption of lindane occurs in workers exposed to lindane in 
their occupation [2]. Approximately 9% of a dose of radio-
labeled lindane applied to the forearm as an acetone solution 
appears in the urine [3). Further evidence supporting significant 
transcu taneous absorption of lindane in humans comes from 
the recent observations [ 4-7) that toxicity occurs when this 
compou nd is used repeatedly or in higher doses than recom-
mended by the official label. Although the transcutaneous 
absorption of 1% lindane cream is stated to be "minimal" [8], 
the extend of systemic absorption of lindane from dosage forms 
used clinically has not been studied in humans, despite their 
long and widespread 1_1se. . . 
Lindane induces microsomal drug metabolism m laboratory 
animals [2,6) and accelerates antipyrine metabolism in h umans 
[2] who have been exposed as a result of ~heir occupation. as 
exterminators. T h e current study was designed to determme 
whether the amount of lindane absorbed from a commercially 
available 1% cream applied topically was sufficient to induce 
hepatic metabolism of antipyrine. As a more specific measure 
of lindane absorption from this topical dosage form, we deter-
mined plasma lindane levels. 
METHODS 
Five male and 4 female volunteers, aged 20-33, comprised the study 
group. Their weight was 70.8 ± 4.3 (SE) kg (range 50-91) and surface 
area was 1.77 ± 0.7 M 2 (range 1.48-1.99). Three female volunteers 
comprised the control group (Table I) . All subjects gave written, 
informed consent prior to participation and all were judged to be 
healthy on the basis of a history, physical examination and a series qf 
laboratory tests on blood and urine. None of the subjects had known, 
prior exposure to lindane nor a history of heavy use of alcohol or 
cigarettes and did not alter their use of the .latter during the study. 
Antipyrine, 10 mg/kg body weight, was adminiStered mtraveneously 
over 2 min to all volunteers who had fasted for at least 8 hr and 
continued to do so for an additional 2 hr. Blood was obtained at 0, 3, 6, 
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9, 12, and 24 hr after the administration of antipyrine. The plasma was 
separated and frozen until analyzed. Urine was collected from 0 to 48 
hr in 2 24-hr aliquots. Two to 3 days later, 1% lindane cream (Kwell, 
Reed and Carnrick, Kenilworth, N .J.) was applied by the same person 
to the entire skin surface (except for a small area in one antecubital 
fossa) in a uniform, thin layer as recommended by the official label. 
The cream was left on for 12 hr and then washed off by showering with 
soap and water. The dose (determined from the difference in weight of 
the tube before and after application) varied from 152 to 348 mg 
lindane/M" (mean 274) (Table l) . The control subjects had the cream 
vehicle without lindane applied in a similar fashion, left on for 12 hr 
and then removed as above. AU subjects were cautioned to avoid 
accidental ingestion of lindane by contact of the fingers with the mouth. 
Seventy-two hours thereafter, plasma was obtained for analysis of 
lindane concentration. The venipuncture to obtain this blood was done 
through the skin in the antecubital fossa to which lindane had not been 
applied. Seven days follow ing application of the lindane, antipyrine was 
again administered intraveneously and plasma and urine collected again 
as described (supra vide) . 
P lasma antipyrine concentrations were measured by gas- liquid chro-
matography (GLC) as described previously [10,11]. The excretion of 
6,8-hydroxycortisol was measured in the 24-hr urine samples collected 
just before and 7 days after lindane application [12]. Plasma and urine 
lindane concentrations were assayed using the GLC procedure de-
scribed by Palmer and Kolmodin-Hedman [13]. 
Plasma elimination half-life (t 1d, volume of distribution (Vd) and 
plasma clearance (Cl) were calculated using standard methods. The 
values obtained before and after the application of lindane cream were 
compared for statistically significant differences using Student's paired 
t-test. A p-value < 0.05 was considered significant. 
RESULTS 
Lindane was undetectable in the plasma of all 12 subjects 
prior to application of the lindane cream. The plasma concen-
tration of lindane increased to 10.3 ± 2.2 ng/ ml (range 2-24) in 
those subjects to whom the lindane cream was applied and 
remained undetectable in those to whom the vehicle alone was 
applied (Table II) . The application of lindane cream signifi-
cantly decreased the antipyrine t 112 from 14.0 ± 4.9 to 10.9 ± 1.8 
hr ( p < 0.05). The Cl concomitantly increased from 0.027 ± 
0.009 to 0.037 ± .011 1/ kg/ hr (p < 0.05) (Fig 1). Vc~ was not 
TABLE I. Subject charac.teristics and dose of lindane 
Experimental subject.s Sex Weight kg Su rface Lindane applied 
area M:! mg mg/ M' 
l M 67 1.53 2.30 216 
2 M 72 1.84 500 272 
3 M 83 1.98 490 247 
4 M 79 1.98 300 152 
5 F 50 1.48 500 338 
6 F 55 1.67 560 335 
7 F 70 1.55 540 348 
8 F 91 1.99 520 261 
9 M 70 1.88 560 298 
Mean 71 1.77 478 274 
SE 4.2 0.07 32 20 
Control subjects 
10 F 53 1.58 0 0 
11 F 47 1.51 0 0 
12 F 56 1.64 0 0 
Mean 52 1.58 0 0 
SE 3 .04 0 0 
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TABLE II. The effect of topical application of 1% lindane cream on 
plasma lindane concentration and excretion of 6{3 -hydroxycortisol in 
the urine 
and little correlation with the dose administered, the concen-
tration of lindane obtained approximate those previously noted 
in humans chronically exposed to the pesticide [2]. 
6B-Hydroxycortisol1' mg/ 24 hr 
Experimental subjects Plasma lindane" urine 
ng/ ml 
Pre-lindane Afte r lindane 
I 11 0.44 0.34 
2 16 0.55 0.33 
3 10 0.38 0.37 
4 4 0.44 0.55 
5 5 0.28 0.43 
6 8 0.37 0.76 
7 24 0.35 0.29 
8 11 1.42 1.89 
9 4 0.36 0.47 
Mean 10.3 0.51 0.60 
SE 2.2 0.12 0.17 
Cont rol subjec ts 
10 0 .56 .43 
ll 0 .79 .48 
12 0 2.08 .59 
Mean 1.14 .50 
SE 0.47 .29 
'' Determined 72 hr after topical application of 1% lindane cream. 
1
' Determined 7 days after topical application of 1% lindane cream. 
Vd l/kg 
p> .OS 
8 
A 
Cl 1/kg -hr 
A 
FI G l. Correla tion between antipyrine elimination half life (t 'h ) prior 
to application (init ial) of 1% lindane cream and percent decrease in t'h 
7 days afte r a pplication. 
al tered significantly. None of these 3 parameters changed sig-
nificantly in control subjects receiving just the vehicle. The 
percent decrease in t1 ;1 correlated significantly with the pre-
treatment t 1;1 (Fig 2) , but with neither the plasma concentration 
nor the dose of lindane, whether the latter was expressed as the 
actual concentration or related to weight or surface area. Only 
minute amounts of unchanged lindane were detected in the 
urine. The 24-hr excretion of 6~-hydroxycortisol in the urine 
was not altered significantly (Table II) . No correlation was 
observed between t1 ;1 of antipyrine, Cl of antipyrine or plasma 
lindane concentration and the excretion of 6/3-hydroxycortisol 
in the urine. 
DISCUSSION 
Lindane has been implicated in toxic reactions in patients 
when used in excessive amounts or repeatedly as a 1% cream or 
lotion [ 4-7]. This pesticide has previously been associated with 
enhancement of antipyrine metabolism in pesticide workers 
[2,14]. We have now demonstrated that when applied as 1% 
cream in a fashion simulating clinical usage, sufficient lindane 
is absorbed to result in a biological effect, i.e., an increase in 
antipyrine clearance and a de<:rease in its half-life. Despite 
widely varying plasma lindane concentrations in our subjects 
There are several possible explanations for the lack of cor-
relation between the alteration in antipyrine half-life or clear-
ance and dose (whether expressed as total dose or related to 
body weight or surface area) or plasma concentration. Many 
other environmental factors (e.g., cigarette smoking, high pro-
tein diets) control the quantity of microsomal drug metabolizing 
enzymes and therefore antipyrine metabolism. Some subjects 
may have already been maximally induced. Alternatively, the 
small number of subjects and large intersubject variability may 
have obscured a true correlation. Although previous studies in 
rats have shown a high correlation between hepatic and plasma 
lindane concentrations [2], no such data exist for humans. In 
addition, a correlation between the plasma lindane concentra-
tion and effect on induction (as measured by hexobarbital 
sleeping time) in rats was reported only for levels higher than 
those achieved in our subjects [2]. 
Lindane is extensively metabolized by humans to chloro-
phenols [15] and by bacteria which may be present in the urine 
[16]. Therefore, the quantity of lindane per se in the urine is 
not a good indicator of the amount absorbed by any route. 
Radiolabeled lindane could be used to determine excretion of 
lindane and its metabolites in urine [3], but was not available 
in the topical dosage form used in this study. 
There is conflicting evidence as to whether or not the amount 
of 6[3-hydroxycortisol excreted in the urine predicts induction 
of microsomal drug oxidation [17]. Not only did base line levels 
of this hormone not correlate with the rate of antipyrine clear-
ance, it did not significantly increase in our subjects when 
induction, measured as antipyrine clearance, occurred. 
None of the subjects had obvious cutaneous inflammation. 
Since scabies is usually associated with inflammation and ex-
coriation, routine clinical use of lindane in these individuals 
probably results in greater transcutaneous absorption due to 
disruption of the barrier function of the skin and an increase in 
cutaneous blood flow. 
A strong correlation has been reported to exist between the 
plasma concentration of lindane and its brain concentration 
following cutaneous application in the guinea pig [18] and oral 
feeding in the rat [2]. Thus, central nervous system toxicity 
(presumably related to brain lindane concentration) is likely to 
be correlated with plasma lindane concentrations. Indeed, in a 
study of Hungarian pesticide workers [19] a correlation between 
EEG abnormalities and blood lindane concentrations greater 
than 20 ng/ ml in 15 of 17 subjects was demonstrated. Plasma 
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FI G 2. Pharmacokinetic parameters before (B) and after (A) appli-
cation of 1% lindane cream for 12 hr. t 1h = plasma elimination half life; 
V" = volume of distribution; Cl = plasma clearance. 
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lindane concentrations observed in the present study, coupled 
with the likelihood of even higher levels in patients with scabies, 
suggest that the brain concentration of lindane in patients may 
becom e substantial even when the pesticide is applied topically. 
This provides a rational explanation for the central nervous 
system toxicity . observed with the use of 1% .lindane .cream or 
lotion in excessive doses or for prolonged penods of time. 
, The authors are indebted to Reed and Carnrick, Kenilworth, 
N.J. for providing the Kwell vehicle. 
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Announcement 
A P ediatric Dermatology symposium will be held in Rancho Mirage, California, April 28-30 1980. Co-
sponsored by Eisenhower M edical Center and Stanford University School of Medicine it 'will cover 
practical therapeutic approaches to, and advances in, skin disorders such as genetic dermat~ses, viral and 
fungal infections, infestations and parasites, bullous diseases, atopic dermatitis, acne, psoriasis and 
urticaria. It will also feature workshop demonstrations of pertinent office techniques, with registrant 
participation Accredited AMA postgraduate seminar. For information contact: Paul H. Jacobs, M.D. , 
Department of Dermatology, Stanford University School of M edicine, Stanford, CA 94305. 
